In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.
The U.S. Food and Drug Administration (FDA) is reviewing whether to change the warning label on hormone replacement therapy (HRT) drugs used to treat menopause symptoms, a move many experts say is ...
The timing of hormone replacement therapy may make a big difference in a woman's risk of developing Alzheimer's disease. Starting treatment within five years of menopause may lower the risk by as much ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback